Trial Profile

First in human study of CK-4015089

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CK 4015089 (Primary)
Indications Muscular dystrophies
Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

13 Jan 2025 According to Cytokinetics media release, this phase 1 study in healthy human participants is expected to complete in 2025.
13 Nov 2024 New trial record
11 Nov 2024 According to Cytokinetics media release, company announced that first participants have been dosed in a Phase 1 study of CK-4015089 (CK-089) in healthy human participants.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com